Sugi Predict

Sugi Predict / Compounds / Cp-778875

Cp-778875

Cp-778875

SCHEMBL1600965

CCc1ccc(CSc2ccc(NS(=O)(=O)c3ccc(C)c(C(=O)O)c3)cc2)cc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARA

The experimentally established mechanism targets of Cp-778875. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.58
▸ PABPC1 P11940 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.56
▸ HTT P42858 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ CASP6 P55212 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ GFER P55789 1/20 0.48
▸ MCL1 Q07820 1/20 0.48
▸ BCL2A1 Q16548 1/20 0.48
▸ MAPT P10636 3/20 0.48
▸ UCHL1 P09936 1/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ LMNA P02545 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5388054 0.92 POLB (0.56) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL14437715 0.92 POLB (0.56) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL5386741 0.92 POLB (0.56) POLBPABPC1ALDH1A1HTTCASP6
SCHEMBL5375209 0.91 POLB (0.58) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL5373188 0.91 POLB (0.55) POLBPABPC1ALDH1A1CASP6SMN1; SMN2
SCHEMBL5375322 0.90 POLB (0.54) POLBPABPC1ALDH1A1CASP6SMN1; SMN2
SCHEMBL5376747 0.90 POLB (0.54) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL5390814 0.89 POLB (0.58) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL5369948 0.89 POLB (0.53) POLBPABPC1ALDH1A1HTTNPSR1
SCHEMBL5371856 0.89 POLB (0.53) POLBPABPC1ALDH1A1CASP6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 — — US claimed
CN-1930121-A Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER PROD INC (US) 2007-03-14 — — CN claimed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 — — EP claimed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 — — US claimed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 — — WO claimed
EP-1994015-B1 DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS PFIZER PROD INC (US) 2013-04-24 — — EP disclosed
US-8383660-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2013-02-26 — — US disclosed
US-7919506-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2011-04-05 — — US disclosed
US-20100267765-A1 Pharmaceutical Compositions and Methods for CCR5 Antagonists FELSTEAD STEPHEN JOHN 2010-10-21 — — US disclosed
EP-1996564-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES Pfizer Products Incorporated (US) 2008-12-03 — — EP disclosed
EP-1994015-A1 DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS Pfizer Products Inc. (US) 2008-11-26 — — EP disclosed
WO-2007107843-A1 METHODS OF TREATMENT WITH CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2007-09-27 — — WO disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 — — US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 — — US disclosed
CN-1930121-A Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER PROD INC (US) 2007-03-14 — — CN disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 — — EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 — — US disclosed
WO-2006109170-A2 COMBINATION THERAPY FOR TREATMENT OF CARDIOVASCULAR DISEASES AND RELATED CONDITIONS ESPERION THERAPEUTICS INC. (US) 2006-10-19 — — WO disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 — — US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885PABPC1 3612/4885ALDH1A1 2956/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885PABPC1 3461/4885ALDH1A1 2752/4885
US-20100267765-A1 Pharmaceutical Compositions and Methods for CCR5 Antagonists CETP, CCR5, MTTP POLB 3705/4885PABPC1 3168/4885ALDH1A1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.